nodes	percent_of_prediction	percent_of_DWPC	metapath
Mefloquine—ABCB1—Sorafenib—thyroid cancer	0.0492	0.197	CbGbCtD
Mefloquine—CYP3A4—Vandetanib—thyroid cancer	0.0489	0.196	CbGbCtD
Mefloquine—CYP2D6—Sorafenib—thyroid cancer	0.0463	0.186	CbGbCtD
Mefloquine—ABCB1—Doxorubicin—thyroid cancer	0.0298	0.12	CbGbCtD
Mefloquine—CYP3A4—Sorafenib—thyroid cancer	0.0295	0.118	CbGbCtD
Mefloquine—CYP2D6—Doxorubicin—thyroid cancer	0.0281	0.113	CbGbCtD
Mefloquine—HBA2—neck—thyroid cancer	0.0228	0.161	CbGeAlD
Mefloquine—CYP3A4—Doxorubicin—thyroid cancer	0.0179	0.0716	CbGbCtD
Mefloquine—HBA2—saliva-secreting gland—thyroid cancer	0.0178	0.126	CbGeAlD
Mefloquine—HBA2—thyroid gland—thyroid cancer	0.0109	0.0766	CbGeAlD
Mefloquine—HBA1—head—thyroid cancer	0.0105	0.074	CbGeAlD
Mefloquine—HBA2—head—thyroid cancer	0.00963	0.0679	CbGeAlD
Mefloquine—ADORA1—saliva-secreting gland—thyroid cancer	0.00799	0.0564	CbGeAlD
Mefloquine—HBA1—lymph node—thyroid cancer	0.00734	0.0518	CbGeAlD
Mefloquine—HBA2—lymph node—thyroid cancer	0.00674	0.0476	CbGeAlD
Mefloquine—ADORA2A—head—thyroid cancer	0.00501	0.0354	CbGeAlD
Mefloquine—ADORA1—thyroid gland—thyroid cancer	0.00488	0.0344	CbGeAlD
Mefloquine—ACHE—thyroid gland—thyroid cancer	0.00485	0.0342	CbGeAlD
Mefloquine—ADORA1—head—thyroid cancer	0.00433	0.0305	CbGeAlD
Mefloquine—CYP19A1—thyroid gland—thyroid cancer	0.00331	0.0233	CbGeAlD
Mefloquine—ADORA1—lymph node—thyroid cancer	0.00303	0.0214	CbGeAlD
Mefloquine—BCHE—trachea—thyroid cancer	0.00301	0.0213	CbGeAlD
Mefloquine—ACHE—lymph node—thyroid cancer	0.00301	0.0212	CbGeAlD
Mefloquine—CYP19A1—head—thyroid cancer	0.00293	0.0207	CbGeAlD
Mefloquine—BCHE—thyroid gland—thyroid cancer	0.00238	0.0168	CbGeAlD
Mefloquine—BCHE—head—thyroid cancer	0.00211	0.0149	CbGeAlD
Mefloquine—CYP19A1—lymph node—thyroid cancer	0.00206	0.0145	CbGeAlD
Mefloquine—Oedema—Vandetanib—thyroid cancer	0.00205	0.00368	CcSEcCtD
Mefloquine—Nervous system disorder—Vandetanib—thyroid cancer	0.00201	0.00361	CcSEcCtD
Mefloquine—Thrombocytopenia—Vandetanib—thyroid cancer	0.002	0.0036	CcSEcCtD
Mefloquine—Skin disorder—Vandetanib—thyroid cancer	0.00199	0.00357	CcSEcCtD
Mefloquine—Blister—Epirubicin—thyroid cancer	0.00198	0.00357	CcSEcCtD
Mefloquine—Neuritis—Epirubicin—thyroid cancer	0.00192	0.00344	CcSEcCtD
Mefloquine—Connective tissue disorder—Sorafenib—thyroid cancer	0.00191	0.00343	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00186	0.00335	CcSEcCtD
Mefloquine—Insomnia—Vandetanib—thyroid cancer	0.00185	0.00333	CcSEcCtD
Mefloquine—Paraesthesia—Vandetanib—thyroid cancer	0.00184	0.0033	CcSEcCtD
Mefloquine—Erythema multiforme—Sorafenib—thyroid cancer	0.00184	0.0033	CcSEcCtD
Mefloquine—Blister—Doxorubicin—thyroid cancer	0.00184	0.0033	CcSEcCtD
Mefloquine—Dyspnoea—Vandetanib—thyroid cancer	0.00182	0.00328	CcSEcCtD
Mefloquine—Tinnitus—Sorafenib—thyroid cancer	0.00181	0.00326	CcSEcCtD
Mefloquine—Flushing—Sorafenib—thyroid cancer	0.0018	0.00324	CcSEcCtD
Mefloquine—Cardiac disorder—Sorafenib—thyroid cancer	0.0018	0.00324	CcSEcCtD
Mefloquine—Dyspepsia—Vandetanib—thyroid cancer	0.0018	0.00324	CcSEcCtD
Mefloquine—Decreased appetite—Vandetanib—thyroid cancer	0.00178	0.0032	CcSEcCtD
Mefloquine—Neuritis—Doxorubicin—thyroid cancer	0.00177	0.00319	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00177	0.00318	CcSEcCtD
Mefloquine—Fatigue—Vandetanib—thyroid cancer	0.00176	0.00317	CcSEcCtD
Mefloquine—Angiopathy—Sorafenib—thyroid cancer	0.00176	0.00317	CcSEcCtD
Mefloquine—Mediastinal disorder—Sorafenib—thyroid cancer	0.00175	0.00315	CcSEcCtD
Mefloquine—Alopecia—Sorafenib—thyroid cancer	0.00172	0.00309	CcSEcCtD
Mefloquine—Mental disorder—Sorafenib—thyroid cancer	0.0017	0.00306	CcSEcCtD
Mefloquine—Erythema—Sorafenib—thyroid cancer	0.00169	0.00304	CcSEcCtD
Mefloquine—Malnutrition—Sorafenib—thyroid cancer	0.00169	0.00304	CcSEcCtD
Mefloquine—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00167	0.00301	CcSEcCtD
Mefloquine—Cardiovascular disorder—Epirubicin—thyroid cancer	0.00163	0.00293	CcSEcCtD
Mefloquine—Muscle spasms—Sorafenib—thyroid cancer	0.00163	0.00292	CcSEcCtD
Mefloquine—Abdominal pain—Vandetanib—thyroid cancer	0.00162	0.00291	CcSEcCtD
Mefloquine—Body temperature increased—Vandetanib—thyroid cancer	0.00162	0.00291	CcSEcCtD
Mefloquine—Syncope—Sorafenib—thyroid cancer	0.00152	0.00273	CcSEcCtD
Mefloquine—Leukopenia—Sorafenib—thyroid cancer	0.00151	0.00272	CcSEcCtD
Mefloquine—Cardiovascular disorder—Doxorubicin—thyroid cancer	0.00151	0.00271	CcSEcCtD
Mefloquine—Loss of consciousness—Sorafenib—thyroid cancer	0.00149	0.00267	CcSEcCtD
Mefloquine—BCHE—lymph node—thyroid cancer	0.00148	0.0104	CbGeAlD
Mefloquine—Atrioventricular block—Epirubicin—thyroid cancer	0.00147	0.00265	CcSEcCtD
Mefloquine—Asthenia—Vandetanib—thyroid cancer	0.00147	0.00264	CcSEcCtD
Mefloquine—Hypertension—Sorafenib—thyroid cancer	0.00146	0.00263	CcSEcCtD
Mefloquine—Coordination abnormal—Epirubicin—thyroid cancer	0.00146	0.00262	CcSEcCtD
Mefloquine—Pruritus—Vandetanib—thyroid cancer	0.00145	0.0026	CcSEcCtD
Mefloquine—Myalgia—Sorafenib—thyroid cancer	0.00144	0.00259	CcSEcCtD
Mefloquine—Arthralgia—Sorafenib—thyroid cancer	0.00144	0.00259	CcSEcCtD
Mefloquine—ABCB1—trachea—thyroid cancer	0.00144	0.0101	CbGeAlD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00143	0.00257	CcSEcCtD
Mefloquine—Hepatocellular injury—Epirubicin—thyroid cancer	0.00143	0.00257	CcSEcCtD
Mefloquine—Abnormal dreams—Epirubicin—thyroid cancer	0.00141	0.00254	CcSEcCtD
Mefloquine—CYP2D6—head—thyroid cancer	0.0014	0.00988	CbGeAlD
Mefloquine—Diarrhoea—Vandetanib—thyroid cancer	0.0014	0.00252	CcSEcCtD
Mefloquine—Influenza like illness—Epirubicin—thyroid cancer	0.00139	0.0025	CcSEcCtD
Mefloquine—Anaphylactic shock—Sorafenib—thyroid cancer	0.00138	0.00248	CcSEcCtD
Mefloquine—Atrioventricular block—Doxorubicin—thyroid cancer	0.00136	0.00245	CcSEcCtD
Mefloquine—Shock—Sorafenib—thyroid cancer	0.00136	0.00244	CcSEcCtD
Mefloquine—Nervous system disorder—Sorafenib—thyroid cancer	0.00135	0.00243	CcSEcCtD
Mefloquine—Dizziness—Vandetanib—thyroid cancer	0.00135	0.00243	CcSEcCtD
Mefloquine—Thrombocytopenia—Sorafenib—thyroid cancer	0.00135	0.00243	CcSEcCtD
Mefloquine—Coordination abnormal—Doxorubicin—thyroid cancer	0.00135	0.00242	CcSEcCtD
Mefloquine—Aplastic anaemia—Epirubicin—thyroid cancer	0.00134	0.00241	CcSEcCtD
Mefloquine—Neuropathy—Epirubicin—thyroid cancer	0.00134	0.00241	CcSEcCtD
Mefloquine—Skin disorder—Sorafenib—thyroid cancer	0.00134	0.00241	CcSEcCtD
Mefloquine—Hepatocellular injury—Doxorubicin—thyroid cancer	0.00132	0.00238	CcSEcCtD
Mefloquine—Abnormal dreams—Doxorubicin—thyroid cancer	0.00131	0.00235	CcSEcCtD
Mefloquine—Coma—Epirubicin—thyroid cancer	0.00131	0.00235	CcSEcCtD
Mefloquine—Vomiting—Vandetanib—thyroid cancer	0.0013	0.00234	CcSEcCtD
Mefloquine—Rash—Vandetanib—thyroid cancer	0.00129	0.00232	CcSEcCtD
Mefloquine—Dermatitis—Vandetanib—thyroid cancer	0.00129	0.00232	CcSEcCtD
Mefloquine—Influenza like illness—Doxorubicin—thyroid cancer	0.00128	0.00231	CcSEcCtD
Mefloquine—Headache—Vandetanib—thyroid cancer	0.00128	0.0023	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00126	0.00226	CcSEcCtD
Mefloquine—Aplastic anaemia—Doxorubicin—thyroid cancer	0.00124	0.00223	CcSEcCtD
Mefloquine—Neuropathy—Doxorubicin—thyroid cancer	0.00124	0.00223	CcSEcCtD
Mefloquine—Dyspnoea—Sorafenib—thyroid cancer	0.00123	0.00221	CcSEcCtD
Mefloquine—Nausea—Vandetanib—thyroid cancer	0.00122	0.00219	CcSEcCtD
Mefloquine—Dyspepsia—Sorafenib—thyroid cancer	0.00122	0.00218	CcSEcCtD
Mefloquine—Coma—Doxorubicin—thyroid cancer	0.00121	0.00217	CcSEcCtD
Mefloquine—Decreased appetite—Sorafenib—thyroid cancer	0.0012	0.00216	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00119	0.00214	CcSEcCtD
Mefloquine—Fatigue—Sorafenib—thyroid cancer	0.00119	0.00214	CcSEcCtD
Mefloquine—Hepatic failure—Epirubicin—thyroid cancer	0.00115	0.00208	CcSEcCtD
Mefloquine—ABCB1—thyroid gland—thyroid cancer	0.00114	0.00801	CbGeAlD
Mefloquine—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00113	0.00203	CcSEcCtD
Mefloquine—Urticaria—Sorafenib—thyroid cancer	0.0011	0.00197	CcSEcCtD
Mefloquine—Abdominal pain—Sorafenib—thyroid cancer	0.00109	0.00196	CcSEcCtD
Mefloquine—Body temperature increased—Sorafenib—thyroid cancer	0.00109	0.00196	CcSEcCtD
Mefloquine—Dermatitis bullous—Epirubicin—thyroid cancer	0.00109	0.00195	CcSEcCtD
Mefloquine—Hepatic failure—Doxorubicin—thyroid cancer	0.00107	0.00192	CcSEcCtD
Mefloquine—Affect lability—Epirubicin—thyroid cancer	0.00102	0.00184	CcSEcCtD
Mefloquine—Hypersensitivity—Sorafenib—thyroid cancer	0.00102	0.00183	CcSEcCtD
Mefloquine—ABCB1—head—thyroid cancer	0.00101	0.00711	CbGeAlD
Mefloquine—Dermatitis bullous—Doxorubicin—thyroid cancer	0.001	0.00181	CcSEcCtD
Mefloquine—Asthenia—Sorafenib—thyroid cancer	0.00099	0.00178	CcSEcCtD
Mefloquine—Mood swings—Epirubicin—thyroid cancer	0.000983	0.00177	CcSEcCtD
Mefloquine—Pruritus—Sorafenib—thyroid cancer	0.000977	0.00176	CcSEcCtD
Mefloquine—Ataxia—Epirubicin—thyroid cancer	0.000976	0.00175	CcSEcCtD
Mefloquine—Affect lability—Doxorubicin—thyroid cancer	0.000945	0.0017	CcSEcCtD
Mefloquine—Diarrhoea—Sorafenib—thyroid cancer	0.000944	0.0017	CcSEcCtD
Mefloquine—Muscular weakness—Epirubicin—thyroid cancer	0.000915	0.00165	CcSEcCtD
Mefloquine—Dizziness—Sorafenib—thyroid cancer	0.000913	0.00164	CcSEcCtD
Mefloquine—Mood swings—Doxorubicin—thyroid cancer	0.00091	0.00164	CcSEcCtD
Mefloquine—Ataxia—Doxorubicin—thyroid cancer	0.000903	0.00162	CcSEcCtD
Mefloquine—Vomiting—Sorafenib—thyroid cancer	0.000878	0.00158	CcSEcCtD
Mefloquine—Rash—Sorafenib—thyroid cancer	0.00087	0.00156	CcSEcCtD
Mefloquine—Dermatitis—Sorafenib—thyroid cancer	0.000869	0.00156	CcSEcCtD
Mefloquine—Headache—Sorafenib—thyroid cancer	0.000865	0.00155	CcSEcCtD
Mefloquine—Muscular weakness—Doxorubicin—thyroid cancer	0.000847	0.00152	CcSEcCtD
Mefloquine—Nausea—Sorafenib—thyroid cancer	0.00082	0.00147	CcSEcCtD
Mefloquine—Pneumonia—Epirubicin—thyroid cancer	0.000804	0.00145	CcSEcCtD
Mefloquine—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.000793	0.00143	CcSEcCtD
Mefloquine—Renal failure—Epirubicin—thyroid cancer	0.000786	0.00141	CcSEcCtD
Mefloquine—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000784	0.00141	CcSEcCtD
Mefloquine—Sweating—Epirubicin—thyroid cancer	0.000767	0.00138	CcSEcCtD
Mefloquine—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000756	0.00136	CcSEcCtD
Mefloquine—Agranulocytosis—Epirubicin—thyroid cancer	0.000746	0.00134	CcSEcCtD
Mefloquine—Pneumonia—Doxorubicin—thyroid cancer	0.000744	0.00134	CcSEcCtD
Mefloquine—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.000734	0.00132	CcSEcCtD
Mefloquine—Bradycardia—Epirubicin—thyroid cancer	0.000731	0.00131	CcSEcCtD
Mefloquine—Renal failure—Doxorubicin—thyroid cancer	0.000727	0.00131	CcSEcCtD
Mefloquine—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.000725	0.0013	CcSEcCtD
Mefloquine—Sweating—Doxorubicin—thyroid cancer	0.000709	0.00128	CcSEcCtD
Mefloquine—Connective tissue disorder—Epirubicin—thyroid cancer	0.000706	0.00127	CcSEcCtD
Mefloquine—ABCB1—lymph node—thyroid cancer	0.000705	0.00498	CbGeAlD
Mefloquine—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.0007	0.00126	CcSEcCtD
Mefloquine—Visual impairment—Epirubicin—thyroid cancer	0.000692	0.00124	CcSEcCtD
Mefloquine—Agranulocytosis—Doxorubicin—thyroid cancer	0.000691	0.00124	CcSEcCtD
Mefloquine—Erythema multiforme—Epirubicin—thyroid cancer	0.000679	0.00122	CcSEcCtD
Mefloquine—Bradycardia—Doxorubicin—thyroid cancer	0.000676	0.00122	CcSEcCtD
Mefloquine—Eye disorder—Epirubicin—thyroid cancer	0.000671	0.00121	CcSEcCtD
Mefloquine—Tinnitus—Epirubicin—thyroid cancer	0.000669	0.0012	CcSEcCtD
Mefloquine—Flushing—Epirubicin—thyroid cancer	0.000666	0.0012	CcSEcCtD
Mefloquine—Cardiac disorder—Epirubicin—thyroid cancer	0.000666	0.0012	CcSEcCtD
Mefloquine—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000653	0.00117	CcSEcCtD
Mefloquine—Angiopathy—Epirubicin—thyroid cancer	0.000651	0.00117	CcSEcCtD
Mefloquine—Mediastinal disorder—Epirubicin—thyroid cancer	0.000647	0.00116	CcSEcCtD
Mefloquine—Chills—Epirubicin—thyroid cancer	0.000644	0.00116	CcSEcCtD
Mefloquine—Visual impairment—Doxorubicin—thyroid cancer	0.00064	0.00115	CcSEcCtD
Mefloquine—Alopecia—Epirubicin—thyroid cancer	0.000634	0.00114	CcSEcCtD
Mefloquine—Mental disorder—Epirubicin—thyroid cancer	0.000629	0.00113	CcSEcCtD
Mefloquine—Erythema multiforme—Doxorubicin—thyroid cancer	0.000628	0.00113	CcSEcCtD
Mefloquine—Erythema—Epirubicin—thyroid cancer	0.000625	0.00112	CcSEcCtD
Mefloquine—Malnutrition—Epirubicin—thyroid cancer	0.000625	0.00112	CcSEcCtD
Mefloquine—Eye disorder—Doxorubicin—thyroid cancer	0.000621	0.00112	CcSEcCtD
Mefloquine—Tinnitus—Doxorubicin—thyroid cancer	0.000619	0.00111	CcSEcCtD
Mefloquine—Flushing—Doxorubicin—thyroid cancer	0.000617	0.00111	CcSEcCtD
Mefloquine—Cardiac disorder—Doxorubicin—thyroid cancer	0.000617	0.00111	CcSEcCtD
Mefloquine—Angiopathy—Doxorubicin—thyroid cancer	0.000603	0.00108	CcSEcCtD
Mefloquine—Muscle spasms—Epirubicin—thyroid cancer	0.000601	0.00108	CcSEcCtD
Mefloquine—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000599	0.00108	CcSEcCtD
Mefloquine—Chills—Doxorubicin—thyroid cancer	0.000596	0.00107	CcSEcCtD
Mefloquine—Vision blurred—Epirubicin—thyroid cancer	0.000589	0.00106	CcSEcCtD
Mefloquine—Alopecia—Doxorubicin—thyroid cancer	0.000587	0.00106	CcSEcCtD
Mefloquine—Mental disorder—Doxorubicin—thyroid cancer	0.000582	0.00105	CcSEcCtD
Mefloquine—Ill-defined disorder—Epirubicin—thyroid cancer	0.00058	0.00104	CcSEcCtD
Mefloquine—Erythema—Doxorubicin—thyroid cancer	0.000578	0.00104	CcSEcCtD
Mefloquine—Malnutrition—Doxorubicin—thyroid cancer	0.000578	0.00104	CcSEcCtD
Mefloquine—Agitation—Epirubicin—thyroid cancer	0.000574	0.00103	CcSEcCtD
Mefloquine—Malaise—Epirubicin—thyroid cancer	0.000564	0.00101	CcSEcCtD
Mefloquine—Vertigo—Epirubicin—thyroid cancer	0.000562	0.00101	CcSEcCtD
Mefloquine—Syncope—Epirubicin—thyroid cancer	0.000561	0.00101	CcSEcCtD
Mefloquine—Leukopenia—Epirubicin—thyroid cancer	0.000559	0.00101	CcSEcCtD
Mefloquine—Muscle spasms—Doxorubicin—thyroid cancer	0.000556	0.001	CcSEcCtD
Mefloquine—Palpitations—Epirubicin—thyroid cancer	0.000552	0.000993	CcSEcCtD
Mefloquine—Loss of consciousness—Epirubicin—thyroid cancer	0.000549	0.000988	CcSEcCtD
Mefloquine—Vision blurred—Doxorubicin—thyroid cancer	0.000545	0.00098	CcSEcCtD
Mefloquine—Convulsion—Epirubicin—thyroid cancer	0.000542	0.000974	CcSEcCtD
Mefloquine—Hypertension—Epirubicin—thyroid cancer	0.00054	0.00097	CcSEcCtD
Mefloquine—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000537	0.000965	CcSEcCtD
Mefloquine—Arthralgia—Epirubicin—thyroid cancer	0.000532	0.000957	CcSEcCtD
Mefloquine—Myalgia—Epirubicin—thyroid cancer	0.000532	0.000957	CcSEcCtD
Mefloquine—Chest pain—Epirubicin—thyroid cancer	0.000532	0.000957	CcSEcCtD
Mefloquine—Agitation—Doxorubicin—thyroid cancer	0.000531	0.000956	CcSEcCtD
Mefloquine—Anxiety—Epirubicin—thyroid cancer	0.00053	0.000953	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000528	0.00095	CcSEcCtD
Mefloquine—Discomfort—Epirubicin—thyroid cancer	0.000526	0.000945	CcSEcCtD
Mefloquine—Malaise—Doxorubicin—thyroid cancer	0.000522	0.000938	CcSEcCtD
Mefloquine—Vertigo—Doxorubicin—thyroid cancer	0.00052	0.000934	CcSEcCtD
Mefloquine—Syncope—Doxorubicin—thyroid cancer	0.000519	0.000932	CcSEcCtD
Mefloquine—Leukopenia—Doxorubicin—thyroid cancer	0.000518	0.000931	CcSEcCtD
Mefloquine—Confusional state—Epirubicin—thyroid cancer	0.000514	0.000925	CcSEcCtD
Mefloquine—Palpitations—Doxorubicin—thyroid cancer	0.000511	0.000919	CcSEcCtD
Mefloquine—Oedema—Epirubicin—thyroid cancer	0.00051	0.000917	CcSEcCtD
Mefloquine—Anaphylactic shock—Epirubicin—thyroid cancer	0.00051	0.000917	CcSEcCtD
Mefloquine—Loss of consciousness—Doxorubicin—thyroid cancer	0.000508	0.000914	CcSEcCtD
Mefloquine—Shock—Epirubicin—thyroid cancer	0.000502	0.000902	CcSEcCtD
Mefloquine—Convulsion—Doxorubicin—thyroid cancer	0.000501	0.000901	CcSEcCtD
Mefloquine—Nervous system disorder—Epirubicin—thyroid cancer	0.0005	0.000899	CcSEcCtD
Mefloquine—Thrombocytopenia—Epirubicin—thyroid cancer	0.000499	0.000898	CcSEcCtD
Mefloquine—Hypertension—Doxorubicin—thyroid cancer	0.000499	0.000898	CcSEcCtD
Mefloquine—Tachycardia—Epirubicin—thyroid cancer	0.000498	0.000895	CcSEcCtD
Mefloquine—Skin disorder—Epirubicin—thyroid cancer	0.000495	0.000891	CcSEcCtD
Mefloquine—Hyperhidrosis—Epirubicin—thyroid cancer	0.000493	0.000887	CcSEcCtD
Mefloquine—Myalgia—Doxorubicin—thyroid cancer	0.000492	0.000885	CcSEcCtD
Mefloquine—Chest pain—Doxorubicin—thyroid cancer	0.000492	0.000885	CcSEcCtD
Mefloquine—Arthralgia—Doxorubicin—thyroid cancer	0.000492	0.000885	CcSEcCtD
Mefloquine—Anxiety—Doxorubicin—thyroid cancer	0.000491	0.000882	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000489	0.000879	CcSEcCtD
Mefloquine—Discomfort—Doxorubicin—thyroid cancer	0.000486	0.000875	CcSEcCtD
Mefloquine—Hypotension—Epirubicin—thyroid cancer	0.000477	0.000857	CcSEcCtD
Mefloquine—Confusional state—Doxorubicin—thyroid cancer	0.000476	0.000856	CcSEcCtD
Mefloquine—Oedema—Doxorubicin—thyroid cancer	0.000472	0.000849	CcSEcCtD
Mefloquine—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000472	0.000849	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000465	0.000836	CcSEcCtD
Mefloquine—Shock—Doxorubicin—thyroid cancer	0.000464	0.000835	CcSEcCtD
Mefloquine—Nervous system disorder—Doxorubicin—thyroid cancer	0.000463	0.000832	CcSEcCtD
Mefloquine—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000462	0.000831	CcSEcCtD
Mefloquine—Insomnia—Epirubicin—thyroid cancer	0.000461	0.00083	CcSEcCtD
Mefloquine—Tachycardia—Doxorubicin—thyroid cancer	0.000461	0.000828	CcSEcCtD
Mefloquine—Skin disorder—Doxorubicin—thyroid cancer	0.000458	0.000824	CcSEcCtD
Mefloquine—Paraesthesia—Epirubicin—thyroid cancer	0.000458	0.000824	CcSEcCtD
Mefloquine—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000456	0.00082	CcSEcCtD
Mefloquine—Dyspnoea—Epirubicin—thyroid cancer	0.000455	0.000818	CcSEcCtD
Mefloquine—Somnolence—Epirubicin—thyroid cancer	0.000453	0.000815	CcSEcCtD
Mefloquine—Dyspepsia—Epirubicin—thyroid cancer	0.000449	0.000807	CcSEcCtD
Mefloquine—Decreased appetite—Epirubicin—thyroid cancer	0.000443	0.000797	CcSEcCtD
Mefloquine—Hypotension—Doxorubicin—thyroid cancer	0.000441	0.000793	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.00044	0.000792	CcSEcCtD
Mefloquine—Fatigue—Epirubicin—thyroid cancer	0.00044	0.000791	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.00043	0.000773	CcSEcCtD
Mefloquine—Insomnia—Doxorubicin—thyroid cancer	0.000427	0.000768	CcSEcCtD
Mefloquine—Paraesthesia—Doxorubicin—thyroid cancer	0.000424	0.000762	CcSEcCtD
Mefloquine—Dyspnoea—Doxorubicin—thyroid cancer	0.000421	0.000757	CcSEcCtD
Mefloquine—Feeling abnormal—Epirubicin—thyroid cancer	0.00042	0.000756	CcSEcCtD
Mefloquine—Somnolence—Doxorubicin—thyroid cancer	0.00042	0.000754	CcSEcCtD
Mefloquine—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000417	0.00075	CcSEcCtD
Mefloquine—Dyspepsia—Doxorubicin—thyroid cancer	0.000415	0.000747	CcSEcCtD
Mefloquine—Decreased appetite—Doxorubicin—thyroid cancer	0.00041	0.000738	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000407	0.000733	CcSEcCtD
Mefloquine—Fatigue—Doxorubicin—thyroid cancer	0.000407	0.000732	CcSEcCtD
Mefloquine—Urticaria—Epirubicin—thyroid cancer	0.000405	0.000729	CcSEcCtD
Mefloquine—Abdominal pain—Epirubicin—thyroid cancer	0.000403	0.000725	CcSEcCtD
Mefloquine—Body temperature increased—Epirubicin—thyroid cancer	0.000403	0.000725	CcSEcCtD
Mefloquine—Feeling abnormal—Doxorubicin—thyroid cancer	0.000389	0.000699	CcSEcCtD
Mefloquine—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000386	0.000694	CcSEcCtD
Mefloquine—Hypersensitivity—Epirubicin—thyroid cancer	0.000376	0.000676	CcSEcCtD
Mefloquine—Urticaria—Doxorubicin—thyroid cancer	0.000375	0.000674	CcSEcCtD
Mefloquine—Abdominal pain—Doxorubicin—thyroid cancer	0.000373	0.000671	CcSEcCtD
Mefloquine—Body temperature increased—Doxorubicin—thyroid cancer	0.000373	0.000671	CcSEcCtD
Mefloquine—Asthenia—Epirubicin—thyroid cancer	0.000366	0.000658	CcSEcCtD
Mefloquine—Pruritus—Epirubicin—thyroid cancer	0.000361	0.000649	CcSEcCtD
Mefloquine—Diarrhoea—Epirubicin—thyroid cancer	0.000349	0.000628	CcSEcCtD
Mefloquine—Hypersensitivity—Doxorubicin—thyroid cancer	0.000348	0.000625	CcSEcCtD
Mefloquine—Asthenia—Doxorubicin—thyroid cancer	0.000339	0.000609	CcSEcCtD
Mefloquine—Dizziness—Epirubicin—thyroid cancer	0.000337	0.000606	CcSEcCtD
Mefloquine—Pruritus—Doxorubicin—thyroid cancer	0.000334	0.0006	CcSEcCtD
Mefloquine—Vomiting—Epirubicin—thyroid cancer	0.000324	0.000583	CcSEcCtD
Mefloquine—Diarrhoea—Doxorubicin—thyroid cancer	0.000323	0.000581	CcSEcCtD
Mefloquine—Rash—Epirubicin—thyroid cancer	0.000322	0.000578	CcSEcCtD
Mefloquine—Dermatitis—Epirubicin—thyroid cancer	0.000321	0.000578	CcSEcCtD
Mefloquine—Headache—Epirubicin—thyroid cancer	0.00032	0.000575	CcSEcCtD
Mefloquine—Dizziness—Doxorubicin—thyroid cancer	0.000312	0.000561	CcSEcCtD
Mefloquine—ADORA2A—GPCR downstream signaling—CALCB—thyroid cancer	0.000306	0.00582	CbGpPWpGaD
Mefloquine—Nausea—Epirubicin—thyroid cancer	0.000303	0.000545	CcSEcCtD
Mefloquine—Vomiting—Doxorubicin—thyroid cancer	0.0003	0.00054	CcSEcCtD
Mefloquine—HBA2—Metabolism—RXRA—thyroid cancer	0.0003	0.0057	CbGpPWpGaD
Mefloquine—Rash—Doxorubicin—thyroid cancer	0.000298	0.000535	CcSEcCtD
Mefloquine—Dermatitis—Doxorubicin—thyroid cancer	0.000297	0.000535	CcSEcCtD
Mefloquine—Headache—Doxorubicin—thyroid cancer	0.000296	0.000532	CcSEcCtD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000284	0.0054	CbGpPWpGaD
Mefloquine—ACHE—ATF-2 transcription factor network—CCND1—thyroid cancer	0.000282	0.00536	CbGpPWpGaD
Mefloquine—Nausea—Doxorubicin—thyroid cancer	0.00028	0.000504	CcSEcCtD
Mefloquine—ADORA2A—Signaling by GPCR—CALCB—thyroid cancer	0.000278	0.00529	CbGpPWpGaD
Mefloquine—ADORA1—GPCR ligand binding—PTCH1—thyroid cancer	0.000276	0.00525	CbGpPWpGaD
Mefloquine—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000275	0.00523	CbGpPWpGaD
Mefloquine—HBA1—Metabolism—SLC5A5—thyroid cancer	0.00027	0.00514	CbGpPWpGaD
Mefloquine—CYP19A1—FSH signaling pathway—AKT1—thyroid cancer	0.000269	0.00512	CbGpPWpGaD
Mefloquine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000268	0.0051	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000261	0.00496	CbGpPWpGaD
Mefloquine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.000256	0.00487	CbGpPWpGaD
Mefloquine—CYP2D6—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000254	0.00484	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000253	0.00482	CbGpPWpGaD
Mefloquine—ADORA1—GPCR ligand binding—SST—thyroid cancer	0.000252	0.0048	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR ligand binding—TSHR—thyroid cancer	0.00025	0.00477	CbGpPWpGaD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—NRG1—thyroid cancer	0.00025	0.00476	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.000245	0.00467	CbGpPWpGaD
Mefloquine—CYP19A1—Biological oxidations—RXRA—thyroid cancer	0.000245	0.00467	CbGpPWpGaD
Mefloquine—ADORA1—GPCR ligand binding—CALCA—thyroid cancer	0.000243	0.00462	CbGpPWpGaD
Mefloquine—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	0.000242	0.00461	CbGpPWpGaD
Mefloquine—ADORA1—Circadian rythm related genes—PPARG—thyroid cancer	0.000241	0.00459	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—CDK1—thyroid cancer	0.00024	0.00456	CbGpPWpGaD
Mefloquine—HBA1—Metabolism—RXRA—thyroid cancer	0.000227	0.00432	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR ligand binding—PTCH1—thyroid cancer	0.000213	0.00405	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CALCB—thyroid cancer	0.000212	0.00404	CbGpPWpGaD
Mefloquine—CYP2D6—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000206	0.00392	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—TRIM33—thyroid cancer	0.000201	0.00383	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—MINPP1—thyroid cancer	0.000196	0.00373	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR ligand binding—SST—thyroid cancer	0.000195	0.00371	CbGpPWpGaD
Mefloquine—ABCB1—HIF-1-alpha transcription factor network—TERT—thyroid cancer	0.000194	0.00369	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—NRG1—thyroid cancer	0.000192	0.00366	CbGpPWpGaD
Mefloquine—HBA2—Metabolism—PPARG—thyroid cancer	0.000189	0.0036	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR ligand binding—CALCA—thyroid cancer	0.000188	0.00357	CbGpPWpGaD
Mefloquine—ADORA2A—Circadian rythm related genes—PPARG—thyroid cancer	0.000186	0.00354	CbGpPWpGaD
Mefloquine—ABCB1—HIF-1-alpha transcription factor network—HIF1A—thyroid cancer	0.000186	0.00353	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—TSHR—thyroid cancer	0.000183	0.00349	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—MINPP1—thyroid cancer	0.00018	0.00343	CbGpPWpGaD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—BRAF—thyroid cancer	0.000178	0.00338	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—MINPP1—thyroid cancer	0.000175	0.00333	CbGpPWpGaD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—BRAF—thyroid cancer	0.000167	0.00318	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—NDUFA13—thyroid cancer	0.000167	0.00317	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—TSHR—thyroid cancer	0.000166	0.00317	CbGpPWpGaD
Mefloquine—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000166	0.00316	CbGpPWpGaD
Mefloquine—ADORA1—Circadian rythm related genes—PTEN—thyroid cancer	0.000165	0.00315	CbGpPWpGaD
Mefloquine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000165	0.00315	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CALCB—thyroid cancer	0.000164	0.00312	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000164	0.00312	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—CHST14—thyroid cancer	0.000157	0.00298	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—TRIM33—thyroid cancer	0.000155	0.00296	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—NDUFA13—thyroid cancer	0.000153	0.00291	CbGpPWpGaD
Mefloquine—HBA2—Metabolism—PTGS2—thyroid cancer	0.000149	0.00283	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—NDUFA13—thyroid cancer	0.000149	0.00283	CbGpPWpGaD
Mefloquine—ACHE—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000145	0.00277	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—CHST14—thyroid cancer	0.000144	0.00274	CbGpPWpGaD
Mefloquine—HBA1—Metabolism—PPARG—thyroid cancer	0.000143	0.00273	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—SST—thyroid cancer	0.000143	0.00271	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—PTCH1—thyroid cancer	0.000142	0.00269	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—TSHR—thyroid cancer	0.000142	0.00269	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—CHST14—thyroid cancer	0.00014	0.00266	CbGpPWpGaD
Mefloquine—ACHE—Phospholipid metabolism—PTEN—thyroid cancer	0.000138	0.00262	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—CALCA—thyroid cancer	0.000137	0.00261	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—BRAF—thyroid cancer	0.000137	0.0026	CbGpPWpGaD
Mefloquine—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000135	0.00256	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—TCF7L1—thyroid cancer	0.000134	0.00256	CbGpPWpGaD
Mefloquine—HBA2—Metabolism—PTEN—thyroid cancer	0.00013	0.00247	CbGpPWpGaD
Mefloquine—BCHE—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.00013	0.00247	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—SST—thyroid cancer	0.000129	0.00246	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—TSHR—thyroid cancer	0.000129	0.00245	CbGpPWpGaD
Mefloquine—ADORA2A—Circadian rythm related genes—PTEN—thyroid cancer	0.000128	0.00243	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000126	0.00241	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—HPGD—thyroid cancer	0.000126	0.0024	CbGpPWpGaD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—PTEN—thyroid cancer	0.000125	0.00238	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—CALCA—thyroid cancer	0.000125	0.00237	CbGpPWpGaD
Mefloquine—BCHE—Phospholipid metabolism—PTEN—thyroid cancer	0.000123	0.00234	CbGpPWpGaD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—CCND1—thyroid cancer	0.000122	0.00232	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	0.000122	0.00232	CbGpPWpGaD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—PTEN—thyroid cancer	0.000118	0.00224	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—HPGD—thyroid cancer	0.000116	0.00221	CbGpPWpGaD
Mefloquine—ADORA1—Circadian rythm related genes—TP53—thyroid cancer	0.000113	0.00215	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—CDK1—thyroid cancer	0.000113	0.00215	CbGpPWpGaD
Mefloquine—HBA1—Metabolism—PTGS2—thyroid cancer	0.000113	0.00215	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—HPGD—thyroid cancer	0.000113	0.00214	CbGpPWpGaD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—NRAS—thyroid cancer	0.000112	0.00213	CbGpPWpGaD
Mefloquine—ACHE—Neuronal System—BRAF—thyroid cancer	0.000111	0.00212	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	0.00011	0.0021	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—SST—thyroid cancer	0.00011	0.0021	CbGpPWpGaD
Mefloquine—CYP2D6—Biological oxidations—RXRA—thyroid cancer	0.000109	0.00208	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—PTCH1—thyroid cancer	0.000109	0.00208	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.000107	0.00203	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	0.000106	0.00202	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—CALCA—thyroid cancer	0.000106	0.00202	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—TCF7L1—thyroid cancer	0.000104	0.00197	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000102	0.00195	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—SST—thyroid cancer	0.0001	0.0019	CbGpPWpGaD
Mefloquine—BCHE—Neuronal System—BRAF—thyroid cancer	9.94e-05	0.00189	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—TSHR—thyroid cancer	9.83e-05	0.00187	CbGpPWpGaD
Mefloquine—HBA1—Metabolism—PTEN—thyroid cancer	9.83e-05	0.00187	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—PRKAR1A—thyroid cancer	9.68e-05	0.00184	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—PTEN—thyroid cancer	9.63e-05	0.00183	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—CALCA—thyroid cancer	9.62e-05	0.00183	CbGpPWpGaD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—KRAS—thyroid cancer	9.62e-05	0.00183	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	9.41e-05	0.00179	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—MEN1—thyroid cancer	9.25e-05	0.00176	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	9.14e-05	0.00174	CbGpPWpGaD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—KRAS—thyroid cancer	9.05e-05	0.00172	CbGpPWpGaD
Mefloquine—ADORA2A—Circadian rythm related genes—TP53—thyroid cancer	8.72e-05	0.00166	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—CDK1—thyroid cancer	8.71e-05	0.00166	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—NRAS—thyroid cancer	8.59e-05	0.00164	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—MINPP1—thyroid cancer	8.53e-05	0.00162	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—PTCH1—thyroid cancer	8.36e-05	0.00159	CbGpPWpGaD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—HRAS—thyroid cancer	8.17e-05	0.00156	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	8.16e-05	0.00155	CbGpPWpGaD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—TP53—thyroid cancer	8.04e-05	0.00153	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—MINPP1—thyroid cancer	8.04e-05	0.00153	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—SST—thyroid cancer	7.65e-05	0.00146	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—TSHR—thyroid cancer	7.59e-05	0.00145	CbGpPWpGaD
Mefloquine—HBA2—Metabolism—AKT1—thyroid cancer	7.48e-05	0.00142	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PRKAR1A—thyroid cancer	7.47e-05	0.00142	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—KRAS—thyroid cancer	7.4e-05	0.00141	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CALCA—thyroid cancer	7.36e-05	0.0014	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—TPR—thyroid cancer	7.25e-05	0.00138	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—NDUFA13—thyroid cancer	7.25e-05	0.00138	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	7.25e-05	0.00138	CbGpPWpGaD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—AKT1—thyroid cancer	7.22e-05	0.00137	CbGpPWpGaD
Mefloquine—CYP3A4—Biological oxidations—RXRA—thyroid cancer	7.15e-05	0.00136	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MEN1—thyroid cancer	7.14e-05	0.00136	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PRKAR1A—thyroid cancer	7.14e-05	0.00136	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—NDUFA13—thyroid cancer	6.83e-05	0.0013	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CHST14—thyroid cancer	6.82e-05	0.0013	CbGpPWpGaD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—AKT1—thyroid cancer	6.79e-05	0.00129	CbGpPWpGaD
Mefloquine—ABCB1—Transmembrane transport of small molecules—TPR—thyroid cancer	6.74e-05	0.00128	CbGpPWpGaD
Mefloquine—ABCB1—Transmembrane transport of small molecules—CP—thyroid cancer	6.74e-05	0.00128	CbGpPWpGaD
Mefloquine—ACHE—Transmission across Chemical Synapses—HRAS—thyroid cancer	6.68e-05	0.00127	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—TPR—thyroid cancer	6.67e-05	0.00127	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CDK1—thyroid cancer	6.66e-05	0.00127	CbGpPWpGaD
Mefloquine—ABCB1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	6.63e-05	0.00126	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PRKAR1A—thyroid cancer	6.56e-05	0.00125	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—TPR—thyroid cancer	6.47e-05	0.00123	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	6.47e-05	0.00123	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PTCH1—thyroid cancer	6.46e-05	0.00123	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CHST14—thyroid cancer	6.43e-05	0.00122	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PRKAR1A—thyroid cancer	6.37e-05	0.00121	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—HRAS—thyroid cancer	6.29e-05	0.0012	CbGpPWpGaD
Mefloquine—ABCB1—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	6.24e-05	0.00119	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	6.12e-05	0.00117	CbGpPWpGaD
Mefloquine—BCHE—Transmission across Chemical Synapses—HRAS—thyroid cancer	5.96e-05	0.00114	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	5.94e-05	0.00113	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—SST—thyroid cancer	5.91e-05	0.00112	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	5.77e-05	0.0011	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CALCA—thyroid cancer	5.68e-05	0.00108	CbGpPWpGaD
Mefloquine—HBA1—Metabolism—AKT1—thyroid cancer	5.67e-05	0.00108	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—AKT1—thyroid cancer	5.55e-05	0.00106	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—HPGD—thyroid cancer	5.5e-05	0.00105	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—SLC5A5—thyroid cancer	5.43e-05	0.00103	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—NRG1—thyroid cancer	5.35e-05	0.00102	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	5.3e-05	0.00101	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—MINPP1—thyroid cancer	5.26e-05	0.001	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—HPGD—thyroid cancer	5.18e-05	0.000986	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CDK1—thyroid cancer	5.15e-05	0.000979	CbGpPWpGaD
Mefloquine—ACHE—Neuronal System—HRAS—thyroid cancer	5.12e-05	0.000975	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	5.09e-05	0.000968	CbGpPWpGaD
Mefloquine—ABCB1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	5.05e-05	0.00096	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—SLC5A5—thyroid cancer	4.99e-05	0.00095	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—SLC5A5—thyroid cancer	4.84e-05	0.000922	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—TERT—thyroid cancer	4.8e-05	0.000914	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	4.79e-05	0.000912	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	4.68e-05	0.00089	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	4.63e-05	0.00088	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—HIF1A—thyroid cancer	4.59e-05	0.000874	CbGpPWpGaD
Mefloquine—BCHE—Neuronal System—HRAS—thyroid cancer	4.57e-05	0.00087	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—RXRA—thyroid cancer	4.56e-05	0.000868	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	4.54e-05	0.000864	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—NDUFA13—thyroid cancer	4.47e-05	0.000851	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	4.44e-05	0.000845	CbGpPWpGaD
Mefloquine—ABCB1—Transmembrane transport of small molecules—RXRA—thyroid cancer	4.24e-05	0.000807	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CHST14—thyroid cancer	4.2e-05	0.0008	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—RXRA—thyroid cancer	4.19e-05	0.000798	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—NRG1—thyroid cancer	4.13e-05	0.000786	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	4.08e-05	0.000776	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—RXRA—thyroid cancer	4.07e-05	0.000775	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—NRAS—thyroid cancer	4.05e-05	0.00077	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	3.96e-05	0.000753	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—BRAF—thyroid cancer	3.8e-05	0.000724	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—TERT—thyroid cancer	3.71e-05	0.000706	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	3.55e-05	0.000676	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—HIF1A—thyroid cancer	3.55e-05	0.000675	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—KRAS—thyroid cancer	3.48e-05	0.000663	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—HPGD—thyroid cancer	3.39e-05	0.000645	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—TPR—thyroid cancer	3.16e-05	0.000601	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	3.16e-05	0.000601	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—NRAS—thyroid cancer	3.12e-05	0.000595	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PRKAR1A—thyroid cancer	3.11e-05	0.000591	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—TPR—thyroid cancer	2.98e-05	0.000566	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—HRAS—thyroid cancer	2.96e-05	0.000564	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—BRAF—thyroid cancer	2.94e-05	0.000559	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	2.93e-05	0.000557	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PPARG—thyroid cancer	2.88e-05	0.000548	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—AKT1—thyroid cancer	2.88e-05	0.000548	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CCND1—thyroid cancer	2.78e-05	0.000528	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—KRAS—thyroid cancer	2.69e-05	0.000512	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—PTEN—thyroid cancer	2.68e-05	0.00051	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	2.67e-05	0.000507	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PPARG—thyroid cancer	2.65e-05	0.000504	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—AKT1—thyroid cancer	2.61e-05	0.000498	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PPARG—thyroid cancer	2.57e-05	0.000489	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—NRAS—thyroid cancer	2.39e-05	0.000455	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—SLC5A5—thyroid cancer	2.36e-05	0.00045	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—HRAS—thyroid cancer	2.29e-05	0.000435	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PTGS2—thyroid cancer	2.27e-05	0.000431	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—SLC5A5—thyroid cancer	2.23e-05	0.000424	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—AKT1—thyroid cancer	2.22e-05	0.000423	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CCND1—thyroid cancer	2.14e-05	0.000408	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PTGS2—thyroid cancer	2.08e-05	0.000396	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PTEN—thyroid cancer	2.07e-05	0.000394	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—KRAS—thyroid cancer	2.06e-05	0.000392	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PTGS2—thyroid cancer	2.02e-05	0.000385	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—AKT1—thyroid cancer	2.02e-05	0.000384	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—RXRA—thyroid cancer	1.99e-05	0.000378	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PTEN—thyroid cancer	1.98e-05	0.000376	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—TPR—thyroid cancer	1.95e-05	0.00037	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	1.91e-05	0.000364	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—RXRA—thyroid cancer	1.87e-05	0.000356	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—NRAS—thyroid cancer	1.85e-05	0.000351	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—TP53—thyroid cancer	1.83e-05	0.000348	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PTEN—thyroid cancer	1.82e-05	0.000346	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PTEN—thyroid cancer	1.76e-05	0.000336	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—HRAS—thyroid cancer	1.75e-05	0.000333	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—KRAS—thyroid cancer	1.59e-05	0.000302	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—AKT1—thyroid cancer	1.54e-05	0.000294	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—SLC5A5—thyroid cancer	1.46e-05	0.000277	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—TP53—thyroid cancer	1.41e-05	0.000269	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—HRAS—thyroid cancer	1.35e-05	0.000257	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PPARG—thyroid cancer	1.25e-05	0.000239	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—RXRA—thyroid cancer	1.22e-05	0.000233	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—AKT1—thyroid cancer	1.19e-05	0.000227	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PPARG—thyroid cancer	1.18e-05	0.000225	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—AKT1—thyroid cancer	1.14e-05	0.000217	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—AKT1—thyroid cancer	1.05e-05	0.000199	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—AKT1—thyroid cancer	1.02e-05	0.000193	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PTGS2—thyroid cancer	9.86e-06	0.000188	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PTGS2—thyroid cancer	9.29e-06	0.000177	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PTEN—thyroid cancer	8.6e-06	0.000164	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PTEN—thyroid cancer	8.11e-06	0.000154	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PPARG—thyroid cancer	7.72e-06	0.000147	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PTGS2—thyroid cancer	6.08e-06	0.000116	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PTEN—thyroid cancer	5.3e-06	0.000101	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—AKT1—thyroid cancer	4.96e-06	9.44e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—AKT1—thyroid cancer	4.67e-06	8.89e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—AKT1—thyroid cancer	3.05e-06	5.81e-05	CbGpPWpGaD
